Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 2/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.46 |
| ▸ | ESR1 | P03372 | 8/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19946013 | 0.85 | ESR1 (0.46) | MMP3ESR2ESR1NEK1AR | |
| SCHEMBL29261464 | 0.84 | CYP11B1 (0.46) | MMP3KIF11ESR2ESR1NEK1 | |
| SCHEMBL31556861 | 0.84 | CYP11B1 (0.46) | MMP3KIF11ESR2ESR1NEK1 | |
| SCHEMBL31551666 | 0.77 | CYP11B1 (0.47) | ESR2ESR1NEK1CYP11B1CYP11B2 | |
| SCHEMBL14213297 | 0.77 | KIF11 (0.50) | KIF11ESR2ESR1ABCB1MEN1 | |
| SCHEMBL14409245 | 0.76 | KIF11 (0.46) | KIF11ESR2ESR1ABCB1MEN1 | |
| SCHEMBL2761139 | 0.76 | MAOB (0.44) | MMP3ESR2NEK1CYP11B1CYP11B2 | |
| SCHEMBL9543269 | 0.74 | ESR2 (0.45) | MMP3ESR2ESR1AR | |
| SCHEMBL28667436 | 0.74 | TYR (0.58) | MMP3ESR2ESR1MEN1KMT2A | |
| SCHEMBL29700948 | 0.74 | IDO1 (0.48) | NEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | MMP3 530/4885KIF11 4586/4885ESR2 135/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | MMP3 4755/4885KIF11 370/4885ESR2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.